Drug-induced hyperprolactinemia.
Bandyopadhyay P.
Drugs Today (Barc). 2006 Feb;42(2):103-19. doi: 10.1358/dot.2006.42.2.953592.
Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.
Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA; Endocrine Society.
J Clin Endocrinol Metab. 2011 Feb;96(2):273-88. doi: 10.1210/jc.2010-1692.
Drug induced hypoprolactinemia.
Ioachimescu AG, Kelestimur F.
Rev Endocr Metab Disord. 2024 Dec;25(6):1003-1011. doi: 10.1007/s11154-024-09909-6. Epub 2024 Sep 23.
Antipsychotic drug-induced hyperprolactinemia: clinical implications.
Molitch ME.
Endocr Pract. 2000 Nov-Dec;6(6):479-81.
[Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C.
Encephale. 2014 Feb;40(1):86-94. doi: 10.1016/j.encep.2012.03.002. Epub 2013 Aug 5.
Drug-induced gynecomastia.
Eckman A, Dobs A.
Expert Opin Drug Saf. 2008 Nov;7(6):691-702. doi: 10.1517/14740330802442382.
Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences.
Voicu V, Medvedovici A, Ranetti AE, Rădulescu FŞ.
Expert Opin Drug Metab Toxicol. 2013 Aug;9(8):955-68. doi: 10.1517/17425255.2013.791283. Epub 2013 Apr 21.
Overview of Hyperprolactinemia: General Approach and Reproductive Health Implications.
Haidenberg-David F, Sidauy-Adissi J, Moscona-Nissan A, Jonguitud-Zumaya E, Fugarolas-Morinelli M, Martinez-Mendoza F, Taniguchi-Ponciano K, Marrero-Rodríguez D, Mercado M.
Arch Med Res. 2024 Dec;55(8):103102. doi: 10.1016/j.arcmed.2024.103102. Epub 2024 Oct 24.
Drug-induced Hyperprolactinemia Results in Atypical Atypical Fracture.
Lee I, Son DW, Park JH, Park JH.
Hip Pelvis. 2021 Jun;33(2):102-107. doi: 10.5371/hp.2021.33.2.102. Epub 2021 Jun 4.
Drug-induced sexual dysfunction.
Aldridge SA.
Clin Pharm. 1982 Mar-Apr;1(2):141-7.
